5 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 1 | Terminated 1 |
Follow Vulvar Neoplasms: new trials by email Literature Review of Vulvar Neoplasms trials Research Report on Vulvar Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| AK104 for Recurrent or Metastatic Vulvar Cancer AK104, AK104+ Paclitaxel+Cisplatin or Carboplatin - Vulvar Cancer | Phase 2 | Terminated | Akeso | 20 | 2023-08-25 | 2026-09-28 |
| Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study Explantation, Quality-of-Life Assessment, Questionnaire Administration - Low Anterior Resection Syndrome, Malignant Anal Neoplasm | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2019-04-12 | 2023-08-14 |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
| Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Antineoplaston therapy (Atengenal + Astugenal) - Cervical Cancer Stage IV, Vulvar Cancer, Stage IV | Phase 2 | Terminated | Burzynski Research Institute | 8 | 1996-06-03 | 2017-09-29 |
Uterine Cervical Neoplasms (4) · Vaginal Neoplasms (3) · Anus Neoplasms (2) · Ovarian Neoplasms (2) · Uterine Neoplasms (2) · Adenocarcinoma, Mucinous (1) · Anal Canal Carcinoma (1) · Carcinosarcoma (1) · Cystadenocarcinoma, Serous (1) · Fallopian Tube Neoplasms (1) · Low Anterior Resection Syndrome (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pelvic Neoplasms (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Vulvar Diseases (5) · Neoplasms (4) · Uterine Cervical Diseases (4) · Uterine Diseases (4) · Vaginal Diseases (3) · Adnexal Diseases (2) · Anus Diseases (2)
Axitinib (1) · Carboplatin (1) · Device Removal (1) · Disulfides (1) · Immunoglobulin G (1) · MEDI0457 (1) · VGX-3100 (1) · antineoplaston A10 (1) · antineoplaston AS 2-1 (1) · durvalumab (1) · rocakinogene sifuplasmid (1)
M.D. Anderson Cancer Center (2) · Akeso (1) · Burzynski Research Institute (1) · Incyte Corporation (1)
United States (3) · China (1) · United Kingdom (1)
Craig A Messick, MD (1) · Michael M Frumovitz (1) · Philomena Colucci (1) · Stanislaw R. Burzynski, MD, PhD (1)
2023 (1)